Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RX-0201 + gemcitabine
- Development stage
- Unknown
- Lead developer
- Rexahn Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
RX-0201 (also known as Archexin) is an antisense oligonucleotide designed to target and inhibit the expression of AKT1 by binding to its mRNA, thereby reducing downstream AKT signaling. It is being developed primarily for oncology indications, including metastatic renal cell carcinoma and pancreatic cancer. Gemcitabine is a nucleoside analog chemotherapeutic agent that acts as a prodrug; it is metabolized intracellularly into active diphosphate and triphosphate forms that inhibit ribonucleotide reductase and are incorporated into DNA, leading to inhibition of DNA synthesis and induction of apoptosis. The combination of RX-0201 with gemcitabine has been studied in clinical trials for metastatic pancreatic cancer[2][4][6].
- Brand names
- Gemzar
- Other names
- Archexingemcitabine
02
Targets
DNAAKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)RRM1
Beyond the preview
Go deeper on RX-0201 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RX-0201 + gemcitabine.